CoChat

Cardiovascular and heart failure safety profile of vildagliptin: a meta‐analysis of 17 000 patients

McInnes, G., Evans, M., Del Prato, S., Stumvoll, M., Schweizer, A., Lukashevich, V., Shao, Q., Kothny, W. · 2015 · Diabetes, Obesity and Metabolism
Cited by 107

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Aims: To report the cardiovascular ( CV ) safety profile and heart failure ( HF ) risk of vildagliptin from a large pool of studies, including trials in high‐risk patients with type 2 diabetes mellitus ( T2DM ), such as those with congestive HF and/or moderate/severe renal impairment. Methods: We conducted a retrospective meta‐analysis of prospectively adjudicated CV events. Patient‐level data were pooled from 40 double‐blind, randomized controlled phase III and IV vildagliptin studies. The primary endpoint was occurrence of major adverse CV events ( MACEs ; myocardial infarction, stroke and CV death). Assessments of the individual MACE components and HF events (requiring hospitalization or new onset) were secondary endpoints. The risk ratio ( RR ) of vildagliptin (50 mg once‐ and twice‐daily combined) versus comparators (placebo and all non‐vildagliptin treatments) was calculated using the M antel– H aenszel ( M–H ) method. Results: Of the 17 446 patients, 9599 received vildagliptin (9251.4 subject‐years of exposure) and 7847 received comparators (7317.0 subject‐years of exposure). The mean age of the patients was 57 years, body mass index 30.5 kg/m 2 (nearly 50% obese), glycated haemoglobin concentration 8.1% and T2DM duration 5.5 years. A MACE occurred in 83 (0.86%) vildagliptin‐treated patients and 85 (1.20%) comparator‐treated patients, with an M‐H RR of 0.82 [95% confidence interval ( CI ) 0.61–1.11]. Similar RRs were observed for the individual events. Confirmed HF events were reported in 41 (0.43%) vildagliptin‐treated patients and 32 (0.45%) comparator‐treated patients, with an M–H RR 1.08 (95% CI 0.68–1.70). Conclusions: This large meta‐analysis indicates that vildagliptin is not associated with an increased risk of adjudicated MACEs relative to comparators. Moreover, this analysis did not find a significant increased risk of HF in vildagliptin‐treated patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12548

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 107

Metadata

Authors
McInnes, G., Evans, M., Del Prato, S., Stumvoll, M., Schweizer, A., Lukashevich, V., Shao, Q., & Kothny, W.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2015-09-10
Volume
17
Issue
11
Pages
1085-1092
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1846464686
Cited by
107
References
11
FWCI
12.66
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.